AMAG PHARMACEUTICALS, INC.
DelistedCIK 792977fmd_0YH3F1E9VXW5CTPQBTN710ACBKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2020, 47 periods
Latest annual · FY2019
Millions- Total revenues
- 327
- Gross profit
- 219
- Operating income
- (447)
- Net income
- (468)
- Free cash flow
- (128)
Latest quarter · Q3 FY2020
Millions- Total revenues
- 93
- Gross profit
- 80
- Operating income
- 2
- Net income
- 10
- Free cash flow
- 36
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2016 to FY2019
- -8.9%
- Revenue, 5 yearsFY2014 to FY2019
- +21.3%
- Net income, 5 yearsFY2014 to FY2019
- n/m
AMAG PHARMACEUTICALS, INC. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2019 | FY2018 | Change | Source |
|---|---|---|---|---|
| Revenue | $326.5 million | $472 million | -30.8% | 10-K/A 2020-09-15 · proof |
| Gross profit | $219.4 million | $256.2 million | -14.4% | 10-K/A 2020-09-15 · proof |
| Operating income | -$446.7 million | -$49 million | 10-K/A 2020-09-15 · proof | |
| Net income | -$467.7 million | -$68.5 million | 10-K/A 2020-09-15 · proof | |
| Cash from operating activities | -$125.7 million | $60.8 million | -306.7% | 10-K 2020-03-06 · proof |
| Free cash flow | -$128.2 million | $58.3 million | -320.1% | 10-K 2020-03-06 · proof |
| Total assets | $791.2 million | $1.2 billion | -32.7% | 10-K 2020-03-06 · proof |
| Total liabilities | $511.4 million | $433.9 million | +17.9% | 10-Q 2020-08-17 · proof |
| Cash and cash equivalents | $113 million | $253.3 million | -55.4% | 10-K 2020-03-06 · proof |
| Total debt | $277 million | $283.2 million | -2.2% | 10-K 2020-03-06 · proof |
- What was AMAG PHARMACEUTICALS, INC.'s revenue in fiscal 2019?
- AMAG PHARMACEUTICALS, INC. reported revenue of $326.5 million for fiscal 2019 (the year ended Dec 31, 2019), against $472 million the year before (-30.8%). Source: the 10-K/A filed with the SEC on Sep 15, 2020 (restated). SEC
- What was AMAG PHARMACEUTICALS, INC.'s gross profit in fiscal 2019?
- AMAG PHARMACEUTICALS, INC. reported gross profit of $219.4 million for fiscal 2019 (the year ended Dec 31, 2019), against $256.2 million the year before (-14.4%). Source: the 10-K/A filed with the SEC on Sep 15, 2020 (restated). SEC
- What was AMAG PHARMACEUTICALS, INC.'s operating income in fiscal 2019?
- AMAG PHARMACEUTICALS, INC. reported operating income of -$446.7 million for fiscal 2019 (the year ended Dec 31, 2019), against -$49 million the year before. Source: the 10-K/A filed with the SEC on Sep 15, 2020 (restated). SEC
- What was AMAG PHARMACEUTICALS, INC.'s net income in fiscal 2019?
- AMAG PHARMACEUTICALS, INC. reported net income of -$467.7 million for fiscal 2019 (the year ended Dec 31, 2019), against -$68.5 million the year before. Source: the 10-K/A filed with the SEC on Sep 15, 2020 (restated). SEC
- What was AMAG PHARMACEUTICALS, INC.'s cash from operating activities in fiscal 2019?
- AMAG PHARMACEUTICALS, INC. reported cash from operating activities of -$125.7 million for fiscal 2019 (the year ended Dec 31, 2019), against $60.8 million the year before (-306.7%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What was AMAG PHARMACEUTICALS, INC.'s free cash flow in fiscal 2019?
- AMAG PHARMACEUTICALS, INC. reported free cash flow of -$128.2 million for fiscal 2019 (the year ended Dec 31, 2019), against $58.3 million the year before (-320.1%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What are AMAG PHARMACEUTICALS, INC.'s total assets?
- As of Dec 31, 2019, AMAG PHARMACEUTICALS, INC. reported total assets of $791.2 million, against $1.2 billion a year earlier (-32.7%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What are AMAG PHARMACEUTICALS, INC.'s total liabilities?
- As of Dec 31, 2019, AMAG PHARMACEUTICALS, INC. reported total liabilities of $511.4 million, against $433.9 million a year earlier (+17.9%). Source: the 10-Q filed with the SEC on Aug 17, 2020 (restated). SEC
- What are AMAG PHARMACEUTICALS, INC.'s cash and cash equivalents?
- As of Dec 31, 2019, AMAG PHARMACEUTICALS, INC. reported cash and cash equivalents of $113 million, against $253.3 million a year earlier (-55.4%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What is AMAG PHARMACEUTICALS, INC.'s total debt?
- As of Dec 31, 2019, AMAG PHARMACEUTICALS, INC. reported total debt of $277 million, against $283.2 million a year earlier (-2.2%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:792977&period_type=annual&limit=5"Information only, not investment advice.